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Abstract
The development of gastric cancer (GC) is closely re-
lated to chronic inflammation caused by Helicobacter 
pylori  infection,  and  herpes  virus  entry  mediator 
(HVEM) is a receptor expressed on the surface of leuko-
cytes that mediates potent inflammatory responses in 
animal models. However, the role of HVEM in human 
GC has not been studied. Previously, we showed that 
the interaction of HVEM on human leukocytes with its 
ligand  LIGHT  induces  intracellular  calcium  mobi-
lization, which results in inflammatory responses in-
cluding induction of proinflammatory cytokine pro-
duction and anti-bacterial activities. In this study, we 
report that leukocytes from GC patients express lower 
levels of membrane HVEM (mHVEM) and have lower 
LIGHT-induced bactericidal activities than those from 
healthy controls (HC). In contrast, levels of soluble 
HVEM (sHVEM) in the sera of GC patients were sig-
nificantly higher than in those of HC. We found that 
monocyte membrane-bound HVEM is released into the 
medium when cells are activated by proinflammatory 
cytokines such as TNF-α and IL-8, which are elevated 
in the sera of GC patients. mHVEM level dropped in par-
allel with the release of sHVEM, and release was com-
pletely  blocked  by  the  metalloprotease  inhibitor, 
GM6001. We also found that the low level of mHVEM on 
GC  patient  leukocytes  was  correlated  with  low 
LIGHT-induced bactericidal activities against H. pylori 
and  S.  aureus and production of reactive oxygen 
species. Our results indicate that mHVEM on leuko-
cytes and sHVEM in sera may contribute to the develop-
ment and/or progression of GC.
Keywords: cytokines; inflammation; monocytes; re-
ceptors, tumor necrosis factor, member 14; stomach 
neoplasms; TNFSF14 protein, human 
Introduction
It is now well established that inflammation plays 
critical roles in the development of cancer and 
metastases. Inflammation is caused by many 
agents including microbial infections, autoimmune 
diseases and obesity, and involves complex inter-
actions between proinflammatory cytokines and 
cells (Mantovani et al., 2008). Tumor necrosis fac-
tor  α (TNF-α) is one of the most potent proin-
flammatory cytokines and is involved in the patho-
genesis of many inflammatory diseases and tu-
mors (Balkwill, 2009). Therefore, TNF-α and its re-
ceptors have long been targets in the treatment of 
a variety of human diseases. For example, some 
patients with inflammatory diseases are helped by 
preventing TNF-α from binding to TNF receptors 150    Exp. Mol. Med. Vol. 44(2), 149-158, 2012
Clinopathological characteristics No
Age
  ＜ 60   5
  ＞ 60 10
Sex
  Male    6
  Female     9
Cancer stage
a
  IA    5
  IB    3
  IIA   1
  IIB   3
  IIIA   1
  IIIC   2
Gastritis
b
  Positive    6
  Negative    9
H. pyroli infection
c 
  Positive   1
  Negative   3
  ND
d 11
aTNM stage; 
bdetermined by endoscopy; 
cdetermined by CLO test; 
dnot 
determined
Table 1. Gastric cancer patient characteristics (TNFR). However, some patients are resistant to 
treatment by TNF-α blockade, implying that the 
role of TNF-α is not universal in human diseases 
(Zhu et al., 2010; Benucci et al., 2011). The TNF 
superfamily (TNFSF) and the TNFR superfamily 
(TNFRSF) each contain several members, and 
TNFSF-TNFRSF interactions regulate a number of 
normal and pathological processes, including im-
mune responses, hematopoiesis, morphogenesis, 
tumorigenesis, septic shock, and inflammatory dis-
ease (Aggarwal, 2003). It is likely that additional 
TNFSF-TNFRSF interactions are involved in in-
flammation-induced human diseases including 
those resistant to TNF-α blockade. 
    Herpes virus entry mediator (HVEM), a TNFRSF 
protein, is widely expressed on the plasma mem-
branes of hematopoietic lineage cells, such as T 
cells, B cells, natural killer cells, monocytes, neu-
trophils and dendritic cells (Kwon et al., 1997; Heo 
et al., 2006). HVEM has multiple ligands and is 
unique among TNFRSF proteins in binding to both 
TNFSF and immunoglobulin superfamily (IGSF) 
proteins. In addition to the TNFSF proteins LIGHT 
(homologous to lymphotoxins, shows inducible ex-
pression and competes with herpes simplex virus 
glycoprotein D for HVEM, a receptor expressed by 
T lymphocytes) and lymphotoxin α, the IGSF pro-
teins B and T lymphocyte attenuator (BTLA) and 
CD160 bind to HVEM (Shui et al., 2011), as does 
herpes simplex virus glycoprotein D. When LIGHT 
binds to HVEM, positive co-stimulatory signals are 
delivered through both LIGHT and HVEM that re-
sult in potent leukocyte inflammatory responses, 
such as the production of inflammatory cytokines 
and ROS. On the other hand, binding of HVEM to 
BTLA delivers inhibitory signals by recruiting ty-
rosine phosphatase, and these signals lead to sup-
pression of immune responses. Therefore, HVEM 
can act as a molecular switch, either activating or 
inhibiting immune responses. In this regard, many 
studies have focused on the HVEM/LIGHT/BTLA 
pathway in animal models of tumors, autoimmune 
disease, infection and transplantation (del Rio et 
al., 2010). However, few studies have investigated 
the roles of HVEM and/or LIGHT in human dis-
eases including cancer.
    Gastric cancer (GC) is the second leading cause 
of cancer-related death worldwide, and approx-
imately 700,000 people succumb to it each year. It 
has been shown that Helicobacter pylori, by which 
half the world’s population is infected, is closely as-
sociated with the development of GC, suggesting 
that inflammation is involved in that process 
(Wroblewski et al., 2010). In a previous study, we 
showed that HVEM induces potent inflammatory 
responses by neutrophils and monocytes (Heo et 
al., 2006). Therefore, we hypothesized that leuko-
cytes from GC patients might have altered levels of 
HVEM and HVEM-mediated immune responses. 
Here we report that the leukocytes of GC patients 
contain significantly lower levels of HVEM than 
those of healthy controls, and GC patients have 
higher soluble HVEM concentrations in their sera 
than do healthy controls. Surprisingly, we also 
found that membrane-bound HVEM is shed when 
cells are activated by a variety of stimuli including 
the proinflammatory cytokines IL-8 and TNF-α, 
whose concentrations are highly elevated in the 
sera of GC patients. 
Results
Patient characteristics
A summary of the enrolled patients is presented in 
Table 1. Blood samples from 15 patients with GC 
and 22 healthy controls (HC) were investigated. 
Median age of GC and HC was 59.5 ± 11.4 and 
53.9 ± 2.7 years, respectively. HVEM expression in gastric cancer patients    151
Figure 1. GC patients have lower mHVEM levels in their leukocytes and 
higher sHVEM levels in their sera than healthy controls. (A) Histogram of 
mHVEM expression in monocytes and neutrophils. Monocytes and neu-
trophils of GC patients and healthy controls were purified as described in 
Methods. Cells were stained with FITC-conjugated anti-HVEM antibody 
(open histogram) or isotype control (filled histogram) and analyzed by 
FACS. Results shown are representative of three experiments. (B) 
Percentages of HVEM-expressing monocytes (left panel) and neutrophils 
(right panel) in GC patients and HC were determined as in A. Each dot 
represents the % of HVEM expressing cells in a sample. Horizontal bars 
depict means. (C) sHVEM levels in sera of GC patients and HC. 
Concentrations of sHVEM in sera were determined by ELISA as de-
scribed in Methods. Horizontal bars depict means. Each datum shown is 
the mean of triplicate measurements. ***P ＜ 0.001 compared with con-
trol groups. 
GC patient leukocytes have reduced levels of 
membrane HVEM (mHVEM) 
It has previously been demonstrated by this re-
search group that HVEM was expressed on the 
membranes of T-cells, B-cells, monocytes and 
neutrophils isolated from human peripheral blood 
(Heo et al., 2006). Of those, monocytes and neu-
trophils were the most highly HVEM-expressing 
cells. HVEM expression on the membranes of 
monocytes and neutrophils in GC patients and 
healthy controls (HC) were compared by staining 
cells with fluorescence-labeled anti-HVEM anti-
body and examining them by FACS. As shown in 
Figure 1A, GC patient monocytes had significantly 
lower levels of mHVEM than HC monocytes. When 
analyzed as the percentage of HVEM-expressing 
cells, 94.6 ± 3.5% of HC monocytes expressed 
HVEM, compared with only 49.1 ± 12.8% of GC 
patient monocytes (Figure 1B). The percentage of 
HVEM-expressing neutrophils was also sub-
stantially lower in GC patients than in HC (37.0 ±
9.5% vs 67.7 ± 10.7%).
    It has been shown that soluble HVEM (sHVEM) 
is elevated in patients with allergic and auto-
immune diseases such as allergic asthma, atopic 
dermatitis and rheumatoid arthritis (Jung et al., 
2003). However, sHVEM levels in cancer patients 
has not been reported. Blood levels of sHVEM in 
HC and GC patients were determined by ELISA as 
described in Methods. In sharp contrast with the 
results for membrane-bound HVEM, sHVEM levels 
in GC patient sera were more than 3-fold higher 
than in HC (mean ± SD; 748 ± 461 and 2,619 ±
1,195 pg/ml for HC and GC patients, respectively 
(P ＜ 0.01) (Figure 1C).
High levels of proinflammatory cytokines in GC 
patient sera
Cytokines are major regulators of immune cells af-
fecting receptor expression and cell activation. It 
has been reported that sera of advanced stage GC 
patients contain elevated levels of inflammatory cy-
tokines (Tsujimoto et al., 2010). Serum cytokine 
levels were measured to investigate mechanisms 
underlying altered expression of leukocyte 
mHVEM and sHVEM in GC patients. As shown in 
Figure 2, TNF-α, IL-1β, IL-6, and IL-8 levels were 
significantly higher in the sera of GC patients than 
in those of HC. In contrast, IL-2, IL-4, IL-10 and 
IFN-γ levels were significantly lower, while IL-12 
levels did not differ significantly in GC patients and 
HC. 
Stimulation of monocytes induces release of sHVEM 
with a concurrent decrease of mHVEM 
It has been shown that membrane-associated 
HVEM on T lymphocytes is downregulated when 
the cells are activated (Morel et al., 2000). However, 
the regulation of HVEM expression on leukocytes 
has not been reported. It was hypothesized that 
activation of leukocytes by inflammatory stimulants 
might induce mHVEM release into the extracellular 152    Exp. Mol. Med. Vol. 44(2), 149-158, 2012
Figure 2. Cytokine levels in sera of 
GC patients and HC. Peripheral 
blood from GC patients and HC was 
coagulated to obtain sera. Cytokine 
concentrations in sera were de-
termined with ELISA kits (Endogen, 
MA). Each datum is the mean of 
triplicate measurements. Horizontal 
bars depict means. **P ＜ 0.01 and 
***P ＜ 0.001 compared with HC. 
ns, not significant.
space and lead to the high levels of sHVEM ob-
served in GC patient sera. To test this idea, mono-
cytes were cultured in the presence of a variety of 
cell activating agents, such as LPS, PHA, calcium 
ionophore A23187 and PMA for 24 hr and meas-
ured levels of HVEM on cell membranes (mHVEM), 
and of sHVEM in culture supernatants. As shown 
in Figure 3A, all of those stimulants decreased 
mHVEM and increased sHVEM, indicating that 
non-specific activation of monocytes induces re-
lease of mHVEM into the culture medium. The spe-
cific HVEM ligand, rhLIGHT, also dose-depend-
ently decreased mHVEM and increased sHVEM 
(Figure 3B). Since GC patients have high levels of 
systemic inflammatory cytokines, such as TNF-α 
and IL-8 (Figure 2), it was investigated whether cy-
tokines also affected mHVEM expression on mon-
ocytes and sHVEM levels. As expected, both cyto-
kines decreased mHVEM and increased sHVEM in 
the culture medium (Figure 3C). 
        The release of extracellular protein domains, 
called ectodomain shedding, is now recognized as 
a general mechanism for regulating the function of 
transmembrane proteins. Zinc-based metallopro-
teases, such as metalloprotease disintegrins and 
matrix metalloproteases, mediate the shedding of a 
variety of membrane receptors and cytokines 
(Arribas and Borroto, 2002). To see whether metal-
loproteases are involved in the activation-induced 
release of sHVEM in leukocytes, the effect of 
GM6001, which inhibits a wide spectrum of metal-
loproteases, was studied. Freshly isolated human 
monocytes from HC were stimulated with rhLIGHT, 
rhIL-8 or rhTNF-α in the presence of GM6001 for 
24 hr and mHVEM and sHVEM levels in the culture 
medium were determined. It was found that 
GM6001 progressively inhibited the rhLIGHT-in-
duced decrease of mHVEM and rhLIGHT-medi-
ated increase of sHVEM (Figure 4A). Release of 
monocyte mHVEM by rhIL-8 and rhTNF-α was al-
so inhibited by GM6001 (Figure 4B). These results 
indicate that when monocytes are activated, 
mHVEM is cleaved by a metalloprotease and re-
leased into the culture medium. 
GC patient leukocytes have lower HVEM-mediated 
bactericidal activities and produce less ROS than 
leukocytes of healthy controls
Our finding that mHVEM is low on GC leukocytes 
prompted a test of whether altered mHVEM level 
affected HVEM-mediated leukocyte function. It was 
previously demonstrated by this research group 
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Figure 3. Stimulation of monocytes decreases mHVEM and increases 
sHVEM. (A) Monocytes from HC were cultured in RPMI1640 + 10% FBS 
in the presence of 100 ng/ml LPS, 1 μg/ml PHA, 10 nM A23187, or 50 
ng/ml PMA and 200 ng/ml ionomycin. After 24 hr, cells and culture super-
natants were harvested. Cells were stained with anti-HVEM-FITC mAbs 
or isotype control mAbs (Mouse IgG1) and analyzed by flow cytometry, 
and percentages of mHVEM-expressing cells are shown (left panel). 
Concentrations of sHVEM in culture supernatants were analyzed by 
ELISA (right panel). (B) Monocytes were cultured in the presence of 0, 1, 
10 or 100 ng/ml rhLIGHT for 24 hr, and the % of mHVEM-expressing 
cells and sHVEM concentrations in culture supernatants were de-
termined as in (A). (C) Monocytes were cultured with 100 ng/ml of 
rhLIGHT, rhTNF-α or rhIL-8 for 24 hr, and the % of mHVEM expressing 
cells and sHVEM concentrations in culture supernatants were de-
termined as in (A). Results shown are representative of at least three in-
dependent experiments and are means ± SEM of triplicates. ***P ＜
0.001 compared with rhLIGHT- alone group. mHVEM, membrane bound 
HVEM; sHVEM, soluble HVEM.
Figure  4. Metalloprotease inhibitor GM6001 blocks the activation-in-
duced decrease of mHVEM and increase of sHVEM in cultured 
monocytes. Cells purified from HC were cultured in the presence of the 
indicated agonists (10 ng/ml) and/or GM6001 (10 or 20 μM), and the % 
of mHVEM expressing cells and sHVEM concentrations in culture super-
natants were determined as in Figure 3. Results shown are representa-
tive of at least three independent experiments and are means ± SEM of 
triplicates. ***P ＜ 0.001, **P ＜ 0.01 and, *P ＜ 0.05 compared with 
rhLIGHT alone group. mHVEM, membrane bound HVEM; sHVEM, solu-
ble HVEM.
protein to HVEM in leukocytes activates cytoplas-
mic phospholipase γ1, which results in ROS gen-
eration and enhancement of bactericidal activities 
(Heo et al., 2006, 2007). Neutrophils and mono-
cytes from HC and GC patients were isolated, al-
lowed to ingest S. aureus and incubated with 1, 10, 
and 100 ng/ml of rhLIGHT for 10 min; then the 
number of viable bacteria remaining in the cells 
was determined by plating serial tenfold dilutions of 
cell lysates on agar plates. Figure 5A shows that 
the bactericidal activity of HC monocytes and neu-
trophils was dose-dependently increased by 
rhLIGHT. The bactericidal activities of GC patient 
monocytes and neutrophils were also increased by 
rhLIGHT but to a lesser extent. Heat-inactivated 
rhLIGHT did not enhance the bacterial killing activ-
ity of monocytes and neutrophils, indicating that 
there was no contamination with endotoxins (Figure 
5A). 
    Next, rhLIGHT-induced bactericidal activities of 
GC patient monocytes and neutrophils against H. 
pylori, which is considered as a major agent devel-
oping gastric cancer, was determined. As shown in 
Figure 5B, H. pylori killing activities of GC patient 
monocytes and neutrophils were significantly lower 154    Exp. Mol. Med. Vol. 44(2), 149-158, 2012
Figure 5. HVEM-mediated bacterial killing and ROS production by GC 
patient leukocytes are lower than by HC leukocytes. Monocytes and neu-
trophils of GC patients and healthy controls were purified and incubated 
with opsonized S. aureus or H. pylori for 3 min. After washing to remove 
non-ingested bacteria, (A) cells were incubated for 10 min with indicated 
concentrations of rhLIGHT or (B) cells were treated with 10 ng/ml of 
rhLIGHT for indicated times. After incubation, cells were lysed in distilled 
water, and numbers of viable bacteria per million cells were determined 
by plating on agar. (C) HVEM-mediated ROS production. Cells were 
stained with the ROS-sensitive fluorescent dye, DCF-DA, and cultured 
with 0, 1, 10 or 100 ng/ml of rhLIGHT. After 45 min, they were harvested 
and percentages of ROS-positive cells were assessed by flow cytometry. 
Filled bar, healthy controls; open bar, GC patients. HI-100, heat-in-
activated rhLIGHT 100 ng/ml. Results shown are representative of at 
least three independent experiments from different blood donors and are 
means ± SEM. *P ＜ 0.05; **P ＜ 0.01 and ***P ＜ 0.001 compared 
with control group. 
than those of HC cells. These results indicate that 
GC patient leukocytes have reduced activity of 
HVEM-mediated clearance of H. pylori infection in 
GC patients, which might aggravate inflammation 
associated with GC development.
    ROS, which are produced by activated, phag-
osome-bound NADPH oxidases, are major compo-
nent of the bactericidal activity of monocytes and 
neutrophils and the rhLIGHT-HVEM interaction 
stimulates ROS production in human monocytes 
and neutrophils (Segal, 2005). rhLIGHT-induced 
ROS generation was compared in the leukocytes 
of GC patients and HC. Cells were stained with the 
ROS-sensitive fluorescent dye DCF-DA and in-
cubated with rhLIGHT. They were then harvested, 
and fluorescent cells were detected by flow 
cytometry. As shown in Figure 5B, exposure of HC 
monocytes and neutrophils to rhLIGHT (1 and 10 
ng/ml) stimulated ROS production, but 100 ng/ml 
rhLIGHT had less effect. rhLIGHT treatment of GC 
patient monocytes and neutrophils also increased 
ROS production. However, the % of ROS positive 
GC patient leukocytes was significantly lower than 
in HC leukocytes when compared at the same 
rhLIGHT concentrations, except for neutrophils 
treated with 100 ng/ml of rhLIGHT, which was max-
imally effective in stimulating ROS production. 
These results together with our previous finding 
that rhLIGHT-mediated bactericidal activity in leu-
kocytes is dependent on ROS generation (Heo et 
al., 2006), suggest that mHVEM levels on leuko-
cytes influence HVEM-mediated leukocyte functions. 
Discussion
Ectodomain shedding regulates the activity of a 
number of transmembrane proteins. Several phys-
iological agents, such as chemokines, cytokines, 
growth factors and non-specific agonists such as 
PMA, have been shown to induce ectodomain 
shedding (Arribas and Borroto, 2002). TNFSF and 
TNFRSF proteins have also been shown to be 
regulated by ectodomain shedding. For example, 
TNF-α is synthesized in a transmembrane form, 
proTNF-α, and cleavage by TNF-α converting en-
zyme (TACE; also known as ADAM17), ADAM10 
or MMP-7, releases the receptor-binding domain 
into the extracellular space (Wong et al., 1989; 
Hikita et al., 2009). Ectodomain shedding of HVEM 
has not been previously reported. Our earlier find-
ing that patients with autoimmune disease have 
high levels of sHVEM in their sera is the first report 
of the existence of sHVEM (Jung et al., 2003). We 
observed that levels of sHVEM in sera of patients 
with inflammatory diseases, such as rheumatoid 
arthritis, atopic dermatitis, psoriasis, systemic lu-
pus erythematosus, Bechet's disease, allergic 
asthma or pneumonia, were 2- to 5-fold higher HVEM expression in gastric cancer patients    155
than in sera of healthy controls. In the present 
study, we found that GC patients have roughly 
3-fold higher levels of sHVEM levels in their sera 
than in age-matched healthy controls. Although we 
did not demonstrate cleavage of HVEM, several 
observations suggest that the sHVEM is produced 
by ectodomain shedding rather than by simple 
secretion. The primary feature of ectodomain shed-
ding is that it is induced by non-specific agents 
such as PMA and many agonists (Arribas and 
Borroto, 2002), and we showed that the same was 
true for the increase of sHVEM and decrease of 
mHVEM in cultured monocytes (Figure 3A). Second, 
GC patients have high levels of inflammatory cyto-
kines (Figure 2) and these were shown to induce 
the increase of sHVEM and decrease of mHVEM 
in cultured monocytes (Figure 3C). Lastly, inhibition 
of a metalloprotease known to cause ectodomain 
shedding also inhibited the release of sHVEM by 
cultured monocytes (Figure 4). 
    The soluble domains of receptors generated by 
shedding can regulate ligand functions by inhibiting 
or promoting the formation of active signaling com-
plexes (Rose-John and Heinrich, 1994). Furthermore, 
transmembrane and cytoplasmic domains that re-
main bound to the cell following receptor ectodo-
main shedding have been shown in some cases to 
have autonomous signaling abilities (Fortini, 2001). 
At present, the roles of sHVEM and the trans-
membrane/cytoplamic domain of HVEM are com-
pletely unknown, although the signaling pathway of 
mHVEM is well defined: when LIGHT binds to 
mHVEM, there is intracellular mobilization of cal-
cium ion, and binding of adaptor proteins, referred 
to as TNFR-associated factors, to the cytoplasmic 
domain of HVEM leads to NFκB activation 
(Wallach et al., 1999; Heo et al., 2007). This proc-
ess can result in costimulation of T cells (Tamada 
et al., 2000), induction of dendritic cell maturation 
(Zou et al., 2004), stimulation of Ig production by 
B-cells (Duhen et al., 2004), NK cell activation (Fan 
et al., 2006) and enhancement of the anti-bacterial 
activities of leukocytes (Heo et al., 2006). Researchers 
have reported that administration of an HVEM-Ig 
fusion protein consisting of the soluble extracellular 
domain of HVEM linked to the immunoglobulin Fc 
region affects HVEM-associated physiological 
functions such as mice immune responses to bac-
terial infections, the severity of graft-versus-host 
disease, collagen-induced arthritis, and cardiac al-
lograft rejection (Ye et al., 2002; Pierer et al., 2009; 
Brown et al., 2010). Therefore, there is a good pos-
sibility that the sHVEM generated by ectodomain 
shedding has an in vivo role. Because HVEM has 
multiple ligands, such as LIGHT, BTLA and CD160, 
and LIGHT can bind to LTβR in addition to HVEM, 
sHVEM-mediated affects on molecular interactions 
could be very complex. Such interactions might in-
clude HVEM-LIGHT, HVEM-BTLA, HVEM-CD160 
and LIGHT-LTβR interactions. Identification of the 
role of the sHVEM might suggest ways to interfere 
with gastric cancer development. 
        The immune system can recognize and elimi-
nate transformed tumor cells in a process named 
cancer immunosurveillance. However, the immune 
system can also promote tumor progression. 
These dual anti-tumor and pro-tumor actions of the 
immune system are now referred to as cancer im-
munoediting (Schreiber et al., 2011). Proinflammatory 
cytokines have major effects on the pro-tumor ac-
tivities of the immune system. For example, TNF-α 
produced by tumor cells and leukocytes promotes 
the survival and proliferation of malignant cells, 
stimulates angiogenesis and metastasis, subverts 
adaptive immunity, and alters responses to hor-
mones and chemotherapy (Balkwill, 2009). There 
is good evidence that immune cell-mediated in-
flammation also regulates the development and 
progression of gastric cancers. Thus, the major 
cause of gastric cancer is H. pylori infection, which 
is now recognized as an infectious disease be-
cause chronic H. pylori infection is so closely re-
lated to GC development (Piazuelo et al., 2010). 
Among 1526 Japanese patients who had gastric 
diseases, gastric cancer developed only in those 
patients infected by H. pylori (Uemura et al., 2001). 
Moreover, polymorphisms of several inflammatory 
cytokine genes, such as those for TNF-α and IL-1, 
affect GC risk (Crusius et al., 2008; Seo et al., 
2010). In addition, GC patients have high levels of 
inflammatory cytokines in their sera as shown in 
this study (Figure 2) and by others (Tsujimoto et 
al., 2010). Although the role of HVEM in gastric 
cancer in association with inflammation is un-
known, our finding that GC patient leukocytes have 
low levels of mHVEM but produce high levels of 
sHVEM adds to the evidence that GC is closely as-
sociated with inflammatory processes. Furthermore, 
it is noteworthy that in addition to gastric cancer, 
many cancers, such as hepatocellular carcinoma, 
B-cell lymphoma and cervical carcinoma are 
caused by infectious agents, which are closely as-
sociated with chronic inflammation (Coussens and 
Werb, 2002). Therefore, there is a substantial pos-
sibility that those cancer patients also have altered 
levels of sHVEM and mHVEM in their sera and 
leukocytes. We are currently investigating the level 
of sHVEM and mHVEM in various tumor patients. 156    Exp. Mol. Med. Vol. 44(2), 149-158, 2012
Methods
Reagents 
Recombinant human LIGHT (rhLIGHT) was purchased 
from R&D Systems (Minneapolis, MN), and diluted in 0.1% 
BSA-PBS buffer. According to the suppliers, the endotoxin 
concentration was less than 0.1 ng per 1 μg of protein as 
determined by the LDL method. Recombinant human IL-8 
(rhIL-8), rhTNF-α and rhIL-2 proteins were purchased from 
Endogen (MA, USA). Polymorphprep
TM for purifying neu-
trophils was from Nycomed Pharma (Oslo, Norway) and 
RPMI 1640 and Hank’s balanced salt solution (HBSS), 
from GibcoBRL (Grand Island, N.Y.). ELISA kits for cyto-
kines were purchased from Endogen (Thermo Fisher 
Scientific, Rockford, IL). All other reagents were from Sigma 
(St. Louis, MO). For heat inactivation, proteins were incubated 
for 20 min at 80
oC. 
Test samples
Patients with GC and healthy volunteers were enrolled af-
ter obtaining informed consent, and the study was ap-
proved by the institutional review board of Ulsan University 
Hospital (#09-30). Blood samples were obtained once from 
healthy volunteers and were collected from GC patients 
one day prior to the first chemotherapy treatment at a time 
when they were chemotherapy-naïve. All enrolled in-
dividuals were free from any evidence of infection.
Preparation of monocytes and neutrophils 
Human monocytes and neutrophils were purified from the 
heparinized blood (20 U/ml of heparin) of healthy donors 
and GC patients (Heo et al., 2006). Peripheral blood mono-
nuclear cells (PBMCs) were isolated by centrifugation on a 
Ficoll Hypaque-1077 gradient. Primary CD14
+ monocytes 
were separated from PBMCs by negative selection with 
CD14
+ (Miltenyi Biotec GmbH, Bergisch Gladbach, Germany). 
Neutrophils were purified from adult peripheral blood by 
centrifugation on a Polymorphprep
TM gradient as described 
previously (Heo et al., 2006). After two washes with HBSS 
without Ca
2+ and Mg
2+, cells were resuspended in the ap-
propriate medium. Isolated monocytes and neutrophils 
were more than 95% pure as analyzed by flow cytometry 
and Giemsa staining of cytospin preparations (data not 
shown).
Flow cytometry 
Monocytes (CD14
+ cells) and neutrophils were incubated 
in 20% AB-serum in PBS at 4
oC for 30 min. Subsequently, 
they were washed twice with FACS buffer (PBS containing 
0.3% BSA and 0.1% NaN3) and incubated with FITC-con-
jugated anti-HVEM-FITC mAbs or FITC-conjugated isotype 
control mAbs (Mouse IgG1) at 4
oC for 30 min. Samples 
were analyzed by flow cytometry using a Becton Dickinson 
FACScan flow cytometer, and percentages of mHVEM
+ 
cells were calculated with CELL-Quest software (BD 
Biosciences, San Jose CA). 
Cytokine ELISA 
Sera from patients with GC and healthy controls were har-
vested and frozen at -80
oC. Cytokines were assayed with 
ELISA kits for IFN-γ, IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10, 
IL-12 and TNF-α.
Monocyte culture and ELISA assay for soluble HVEM 
Monocytes were purified from healthy controls and ad-
justed to 2 × 10
6 cells/ml in RPMI1640 medium containing 
10% FBS. They were cultured at 37
oC in the presence of 
various concentrations of rhLIGHT, rhIL-8, rhTNF-α, rhIL-2, 
PMA, ionomycin, LPS, PHA or A23187. After 24 h, cell-free 
supernatants were collected by centrifugation and frozen at 
-80
oC. 
    To measure sHVEM in sera and culture supernatants, 
sandwich ELISAs were employed using two anti-HVEM 
mAbs (108 and 122) recognizing different epitopes (Heo et 
al., 2007). A standard curve was constructed with 
HVEM-Fc as the antigen. ELISA plates were coated with 
100 μg/well of mAb108 (1 μg/ml) and incubated overnight 
at 4
oC. After incubation, plates were washed and blocked 
with PBS containing 4% BSA. Samples diluted in PBS con-
taining 4% BSA were added, and plates were incubated 
overnight at 4
oC. After washing, 100 μl/well of biotin-labeled 
mAb122 at 1 μg/ml in 4% BSA were added and incubation 
continued for 1 h at 37
oC. After addition of streptavidin- 
HRP, plates were developed with TMB substrate solution 
(Endogen, Pierce Biotechnology, Rockford, CA), and ab-
sorbencies at 450 nm were determined. A standard curve 
constructed with HVEM-Fc (R&D system, Minneapolis, MN) 
indicated that the sensitivity limit was 16 pg/ml. HVEM con-
centrations in sera and supernatants were expressed as 
means ± SEM of quadruplicate samples.
Bactericidal activity
Staphylococcus aureus (ATCC 56389; American Type 
Culture Collection, Manassas, VA.) was grown in nutrient 
broth (Becton Dickinson, Sparks, MD.) and Helicobacter 
pylori (ATCC 26695) was grown in Brucella broth (Becton 
Dickinson). Aliquots were frozen at -80
oC and thawed prior 
to use. Killing of bacteria was measured as previously de-
scribed (Heo et al., 2006). Briefly, overnight cultures of S. 
aureus (1 ×10
7 cells/ml) and H. pylori (1 ×10
7 cells/ml) 
were opsonized by incubation with 0.1% gelatin (w/v) and 
10% (v/v) human AB serum in HBSS. One ml of HBSS 
containing 1 ×10
7 opsonized bacteria was added to 1 ×
10
7 cells/ml of monocytes or neutrophils iln 100 μl of HBSS 
and incubated at 37
oC for 3 min with continuous rotation to 
promote phagocytosis. Non-ingested bacteria were dis-
carded by differential centrifugation for 5 min at 1200 rpm, 
and cells containing ingested bacteria were cultured at 
37
oC for 10 min with slow rotation in the presence of 
rhLIGHT or heat inactivated rhLIGHT. Killing was stopped 
by spinning the cells on ice after addition of 1 ml distilled 
water containing 0.01% BSA. Cell clumps were disrupted 
by vigorous vortexing, and the number of viable bacteria 
was determined by plating 10-fold serial dilutions on agar 
plates. The % killing was calculated as follows: % killing = 
[1-(the number of viable bacteria at time t / the number of HVEM expression in gastric cancer patients    157
viable bacteria at time 0)] × 100. 
Measurement of reactive oxygen species (ROS) by 
FACS
ROS generated by monocytes and neutrophils were as-
sayed with the ROS-sensitive fluorescent dye, 2’, 
7’-dichlorofluorescin diacetate (DCF-DA). Cells were 
stained with 5 μM DCF-DA for 15 min at 37
oC in the dark. 
After incubation with DCF-DA, they were washed twice 
with PBS buffer and resuspended in FACs buffer. 
DCF-DA-stained monocytes were then treated with 
rhLIGHT for 45 min. After washing, they were analyzed by 
flow cytometry (FACS Calibur; BD Biosciences, San Jose 
CA), and numbers of DCF-DA positive cells were calcu-
lated and displayed in the form of histograms (Bass et al., 
1983).
Statistics
Differences between experimental groups were evaluated 
by Student's t test. Results are representative of at least 
three independent experiments from different blood donors. 
Data are presented as means ± SEM. 
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